Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19695 | 0.73 | TSHR (0.42) | TSHRHTTLMNAKDM4EMAPT | |
| SCHEMBL27380184 | 0.71 | TSHR (0.41) | TSHRHTTLMNAKDM4EMAPT | |
| SCHEMBL27643306 | 0.71 | TSHR (0.41) | TSHRHTTLMNAKDM4EMAPT | |
| SCHEMBL27594643 | 0.71 | TSHR (0.41) | TSHRHTTLMNAKDM4EMAPT | |
| SCHEMBL21831938 | 0.71 | TSHR (0.41) | TSHRHTTLMNAKDM4EMAPT | |
| SCHEMBL27504674 | 0.71 | TSHR (0.41) | TSHRHTTLMNAKDM4EMAPT | |
| SCHEMBL27643304 | 0.71 | TSHR (0.41) | TSHRHTTLMNAKDM4EMAPT | |
| SCHEMBL452008 | 0.70 | — | — | |
| SCHEMBL452436 | 0.68 | KDM4E (0.30) | KDM4EMAPTALDH1A1POLBMEN1 | |
| SCHEMBL8311252 | 0.68 | EGFR (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150216861-A1 | CYCLOPROPYL AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-08-06 | — | — | US | disclosed |
| US-9029381-B2 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2015-05-12 | — | — | US | disclosed |
| EP-2805937-A1 | Cyclopropyl amide derivatives | AstraZeneca AB (SE) | 2014-11-26 | — | — | EP | disclosed |
| EP-2253615-B1 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2014-07-09 | — | — | EP | disclosed |
| US-8728708-B2 | Photosensitive resin composition, oxime sulfonate compound, method for forming cured film, cured film, organic EL display device, and liquid crystal display device | FUJIFILM CORPORATION (JP) | 2014-05-20 | — | — | US | disclosed |
| EP-2195293-B1 | CYCLOPTOPYL AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-10-16 | — | — | EP | disclosed |
| EP-2613198-A1 | PHOTOSENSITIVE RESIN COMPOSITION, OXIME SULFONATE COMPOUND, METHOD FOR FORMING CURED FILM, CURED FILM, ORGANIC EL DISPLAY DEVICE, AND LIQUID CRYSTAL DISPLAY DEVICE | FUJIFILM Corporation (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-20130171415-A1 | PHOTOSENSITIVE RESIN COMPOSITION, OXIME SULFONATE COMPOUND, METHOD FOR FORMING CURED FILM, CURED FILM, ORGANIC EL DISPLAY DEVICE, AND LIQUID CRYSTAL DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20120065193-A1 | Cyclopropyl Amide Derivatives '978 | ASTRAZENECA AB (SE) | 2012-03-15 | — | — | US | disclosed |
| US-8063215-B2 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2011-11-22 | — | — | US | disclosed |
| EP-2253615-A1 | Cyclopropyl amide derivatives | AstraZeneca AB (SE) | 2010-11-24 | — | — | EP | disclosed |
| EP-2195293-A2 | CYCLOPTOPYL AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2010-06-16 | — | — | EP | disclosed |
| WO-2010062245-A1 | SPIROCYCLOBUTYL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | WO | disclosed |
| US-20100130477-A1 | Spirocyclobutyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| US-20090076020-A1 | Cyclopropyl Amide Derivatives 978 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| WO-2009024823-A2 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
| WO-1998033382-A1 | FUNGICIDAL COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
| US-5721370-A | CHEMILUMINESCENCE | LUMIGEN INC. (US) | 1998-02-24 | — | — | US | disclosed |
| WO-1996036229-A1 | FUNGICIDAL CYCLIC AMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216861-A1 | CYCLOPROPYL AMIDE DERIVATIVES | HRH4, HRH2, HRH3 | TSHR 291/4885HTT 1689/4885LMNA 4640/4885 |
| US-20100130477-A1 | Spirocyclobutyl Piperidine Derivatives | HRH3, HRH4, HRH2 | TSHR 228/4885HTT 1161/4885LMNA 4331/4885 |
| US-20130171415-A1 | PHOTOSENSITIVE RESIN COMPOSITION, OXIME SULFONATE COMPOUND, METHOD FOR FORMING CURED FILM, CURED FILM, ORGANIC EL DISPLAY DEVICE, AND LIQUID CRYSTAL DISPLAY DEVICE | OXER1, OXSR1, RAD51 | TSHR 2444/4885HTT 3417/4885LMNA 3402/4885 |
| US-20090076020-A1 | Cyclopropyl Amide Derivatives 978 | HRH4, HRH2, HRH3 | TSHR 277/4885HTT 1570/4885LMNA 4612/4885 |
| US-20120065193-A1 | Cyclopropyl Amide Derivatives '978 | HRH2, HRH4, HRH3 | TSHR 324/4885HTT 1189/4885LMNA 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.